{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:17:49Z","timestamp":1760660269531,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":2456,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1016\/j.rmed.2006.03.019","type":"journal-article","created":{"date-parts":[[2006,5,27]],"date-time":"2006-05-27T07:15:13Z","timestamp":1148714113000},"page":"2129-2136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III\/IV community-acquired pneumonia patients"],"prefix":"10.1016","volume":"100","author":[{"given":"Andrew F.","family":"Shorr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed M.","family":"Khashab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim X.","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan M.","family":"Tennenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.rmed.2006.03.019_bib1","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1086\/380488","article-title":"Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults","volume":"37","author":"Mandell","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.rmed.2006.03.019_bib2","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0149-2918(98)80144-6","article-title":"The cost of treating community-acquired pneumonia","volume":"20","author":"Niederman","year":"1998","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.rmed.2006.03.019_bib3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJM199701233360402","article-title":"A prediction rule to identify low-risk patients with community-acquired pneumonia","volume":"336","author":"Fine","year":"1997","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.rmed.2006.03.019_bib4","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jama.283.6.749","article-title":"A controlled trial of a critical pathway for treatment of community-acquired pneumonia","volume":"283","author":"Marrie","year":"2000","journal-title":"J Am Med Assoc"},{"issue":"7, Part 2","key":"10.1016\/j.rmed.2006.03.019_bib5","first-page":"89","article-title":"A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study","volume":"21","author":"Feagan","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.rmed.2006.03.019_bib6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0272-5231(05)70239-2","article-title":"Strategies for early discharge of the hospitalized patient with community-acquired pneumonia","volume":"20","author":"Siegel","year":"1999","journal-title":"Clin Chest Med"},{"issue":"3","key":"10.1016\/j.rmed.2006.03.019_bib7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/BF02561528","article-title":"Azithromycin: single 1.5g dose in the treatment of patients with atypical pneumonia syndrome\u2014a randomized study","volume":"27","author":"Schonwald","year":"1999","journal-title":"Infection"},{"issue":"1","key":"10.1016\/j.rmed.2006.03.019_bib8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1179\/joc.1998.10.1.64","article-title":"Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course","volume":"10","author":"Socan","year":"1998","journal-title":"J Chemother"},{"issue":"12","key":"10.1016\/j.rmed.2006.03.019_bib9","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s100960050201","article-title":"Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group","volume":"17","author":"O\u2019Doherty","year":"1998","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.rmed.2006.03.019_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00019048-200202000-00002","article-title":"Predictors of length of hospital stay in community-acquired pneumonia","volume":"11","author":"Stahl","year":"2002","journal-title":"Infect Dis Clin Pract"},{"issue":"7","key":"10.1016\/j.rmed.2006.03.019_bib11","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention","volume":"163","author":"Niederman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"11, Part 2","key":"10.1016\/j.rmed.2006.03.019_bib12","first-page":"302S","article-title":"What do we really know about antibiotic pharmacodynamics?","volume":"21","author":"Gunderson","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.rmed.2006.03.019_bib13","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1378\/chest.119.4.1114","article-title":"Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects","volume":"119","author":"Gotfried","year":"2001","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.rmed.2006.03.019_bib14","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1128\/AAC.47.8.2450-2457.2003","article-title":"Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults","volume":"47","author":"Rodvold","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.rmed.2006.03.019_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0732-8893(02)00417-0","article-title":"Pharmacodynamics of 750mg and 500mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae","volume":"44","author":"Lister","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.rmed.2006.03.019_bib16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1185\/030079904125003304","article-title":"Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens","volume":"20","author":"Dunbar","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.rmed.2006.03.019_bib17","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1086\/377539","article-title":"High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm","volume":"37","author":"Dunbar","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.rmed.2006.03.019_bib18","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1185\/030079904X2556","article-title":"Clinical implications of 750mg, 5-day levofloxacin for the treatment of community-acquired pneumonia","volume":"20","author":"File","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.rmed.2006.03.019_bib19","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1086\/377567","article-title":"Short-course treatment of community-acquired pneumonia","volume":"15;37","author":"Mandell","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.rmed.2006.03.019_bib20","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1592\/phco.21.20.1468.34482","article-title":"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin","volume":"21","author":"Frothingham","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.rmed.2006.03.019_bib21","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1592\/phco.22.8.663.33201","article-title":"Torsades de pointes associated with fluoroquinolones","volume":"22","author":"Owens","year":"2002","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1016\/j.rmed.2006.03.019_bib22","doi-asserted-by":"crossref","first-page":"968","DOI":"10.7326\/0003-4819-141-12-200412210-00021","article-title":"Gatifloxacin-induced hyperglycemia","volume":"141","author":"Happe","year":"2004","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.rmed.2006.03.019_bib23","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1345\/aph.1A480","article-title":"Possible gatifloxacin-induced hypoglycemia","volume":"36","author":"Baker","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.rmed.2006.03.019_bib24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0002-9343(02)01158-0","article-title":"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents","volume":"113","author":"Menzies","year":"2002","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.rmed.2006.03.019_bib25","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0009-9236(03)00009-2","article-title":"Effect of three fluoroquinolones on the QTc interval in healthy volunteers","volume":"73","author":"Noel","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.rmed.2006.03.019_bib26","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/43.4.601","article-title":"Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital","volume":"43","author":"Sevinc","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmed.2006.03.019_bib27","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/archinte.1995.00430120050006","article-title":"Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia","volume":"155","author":"Ramirez","year":"1995","journal-title":"Arch Intern Med"},{"issue":"7, Part 2","key":"10.1016\/j.rmed.2006.03.019_bib28","first-page":"83S","article-title":"Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience","volume":"21","author":"Milkovich","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"22","key":"10.1016\/j.rmed.2006.03.019_bib29","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1093\/ajhp\/59.22.2209","article-title":"Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i. v. to oral","volume":"59","author":"Kuti","year":"2002","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.rmed.2006.03.019_bib30","first-page":"20","article-title":"Cost analysis switching to oral antibiotics: a cost-savings strategy in the hospitalized patient","volume":"8","author":"Ramirez","year":"1996","journal-title":"Drug Benefit Trends"},{"issue":"Suppl 1","key":"10.1016\/j.rmed.2006.03.019_bib31","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1086\/378408","article-title":"Cumulative clinical trial experience with levofloxacin for patients with community-acquired pneumonia-associated pneumococcal bacteremia","volume":"38","author":"Kahn","year":"2004","journal-title":"Clin Infect Dis"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461110600165X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461110600165X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:20:43Z","timestamp":1760610043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095461110600165X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S095461110600165X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2006.03.019","relation":{},"ISSN":["0954-6111"],"issn-type":[{"type":"print","value":"0954-6111"}],"subject":[],"published":{"date-parts":[[2006,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III\/IV community-acquired pneumonia patients","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2006.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}